CL2007002951A1 - USE OF COMPOUNDS DERIVED FROM ESPIROHETEROCICLICOS IN THE TREATMENT OF HYPERCHOLESTEROLEMIA, BENIGNA HYPERPLASIA DE PROSTATA, PRURITIS, CANCER. - Google Patents

USE OF COMPOUNDS DERIVED FROM ESPIROHETEROCICLICOS IN THE TREATMENT OF HYPERCHOLESTEROLEMIA, BENIGNA HYPERPLASIA DE PROSTATA, PRURITIS, CANCER.

Info

Publication number
CL2007002951A1
CL2007002951A1 CL200702951A CL2007002951A CL2007002951A1 CL 2007002951 A1 CL2007002951 A1 CL 2007002951A1 CL 200702951 A CL200702951 A CL 200702951A CL 2007002951 A CL2007002951 A CL 2007002951A CL 2007002951 A1 CL2007002951 A1 CL 2007002951A1
Authority
CL
Chile
Prior art keywords
espiroheterociclicos
benigna
prostata
pruritis
hypercholesterolemia
Prior art date
Application number
CL200702951A
Other languages
Spanish (es)
Inventor
Mehran Seid Chafee Bagherzadeh
Original Assignee
Xenon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenon Pharmaceuticals Inc filed Critical Xenon Pharmaceuticals Inc
Publication of CL2007002951A1 publication Critical patent/CL2007002951A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CL200702951A 2006-10-12 2007-10-12 USE OF COMPOUNDS DERIVED FROM ESPIROHETEROCICLICOS IN THE TREATMENT OF HYPERCHOLESTEROLEMIA, BENIGNA HYPERPLASIA DE PROSTATA, PRURITIS, CANCER. CL2007002951A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US85114206P 2006-10-12 2006-10-12

Publications (1)

Publication Number Publication Date
CL2007002951A1 true CL2007002951A1 (en) 2008-02-01

Family

ID=39092653

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200702951A CL2007002951A1 (en) 2006-10-12 2007-10-12 USE OF COMPOUNDS DERIVED FROM ESPIROHETEROCICLICOS IN THE TREATMENT OF HYPERCHOLESTEROLEMIA, BENIGNA HYPERPLASIA DE PROSTATA, PRURITIS, CANCER.

Country Status (4)

Country Link
AR (1) AR063277A1 (en)
CL (1) CL2007002951A1 (en)
TW (1) TW200833698A (en)
WO (1) WO2008046065A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR053710A1 (en) 2005-04-11 2007-05-16 Xenon Pharmaceuticals Inc SPIROHETEROCICLIC COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS
MY144968A (en) 2005-04-11 2011-11-30 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their uses as therapeutic agents
ATE545416T1 (en) 2006-10-12 2012-03-15 Xenon Pharmaceuticals Inc USE OF SPIRO-OXINDOLE COMPOUNDS AS THERAPEUTICS
JP2011519934A (en) 2008-05-08 2011-07-14 メルク・シャープ・エンド・ドーム・コーポレイション Spiroza indole
CA2741024A1 (en) 2008-10-17 2010-04-22 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
CA2741029A1 (en) 2008-10-17 2010-04-22 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
AR077252A1 (en) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc ESPIROOXINDOL COMPOUND ENANTIOMERS AND THEIR USES AS THERAPEUTIC AGENTS
NZ712378A (en) 2009-10-14 2017-05-26 Xenon Pharmaceuticals Inc Synthetic methods for spiro-oxindole compounds
EP2538919B1 (en) 2010-02-26 2017-07-12 Xenon Pharmaceuticals Inc. Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
TW201636017A (en) 2015-02-05 2016-10-16 梯瓦製藥國際有限責任公司 Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2005035498A1 (en) * 2003-10-08 2006-12-21 住友製薬株式会社 Use of nitrogen-containing bicyclic compounds as food intake regulators
AR053710A1 (en) * 2005-04-11 2007-05-16 Xenon Pharmaceuticals Inc SPIROHETEROCICLIC COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS
MY144968A (en) * 2005-04-11 2011-11-30 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their uses as therapeutic agents

Also Published As

Publication number Publication date
AR063277A1 (en) 2009-01-14
TW200833698A (en) 2008-08-16
WO2008046065A1 (en) 2008-04-17

Similar Documents

Publication Publication Date Title
CL2007002950A1 (en) USE OF COMPOUNDS DERIVED FROM ESPIRO-OXINDOL IN THE TREATMENT OF HYPERCHOLESTEROLEMIA, BENIGNA HYPERPLASIA DE PROSTATA, PRURITIS, CANCER
CL2007002951A1 (en) USE OF COMPOUNDS DERIVED FROM ESPIROHETEROCICLICOS IN THE TREATMENT OF HYPERCHOLESTEROLEMIA, BENIGNA HYPERPLASIA DE PROSTATA, PRURITIS, CANCER.
CL2007002640A1 (en) COMPOUNDS DERIVED FROM 3- (6-OXO-1,6-DIHIDRO-PIRIDIN-3-IL) -BENZAMIDA; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF CANCER.
CL2007002642A1 (en) COMPOUNDS DERIVED FROM 3- (6-OXO-1,6-DIHIDRO-PIRIDIN-3-IL) -BENZAMIDA; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF CANCER.
CL2007002448A1 (en) COMPOUNDS DERIVED FROM PIRIMIDINE CONDENSED WITH HETEROCICLE, MOTOR INHIBITORS; PHARMACEUTICAL COMPOSITION; AND USE FOR CANCER TREATMENT, SUCH AS CANCER DE COLON, OVARIO, LUNG AND PROSTATE.
CL2007002261A1 (en) COMPOUNDS DERIVED FROM IMIDAZO [1,2-B] PIRIDAZINA, QUINASA INHIBITORS; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OR PREVENTION OF CANCER.
CL2007003226A1 (en) COMPOUNDS DERIVED FROM PIRIDINONA; PHARMACEUTICAL COMPOSITION; AND USE TO TREAT CANCER.
CL2007002790A1 (en) COMPOUNDS DERIVED FROM 1H-INDOL AND 1H-BENCIMIDAZOL; PHARMACEUTICAL COMPOSITION; AND USE FOR THE TREATMENT OF HYPOGONADISM, OSTEOPOROSIS AND PROSTATE CANCER BETWEEN OTHERS.
CL2008001234A1 (en) COMPOUNDS DERIVED FROM NITROGEN HETEROCICLES, INHIBITORS OF APOPTOSIS PROTEINS; AND USE IN THE TREATMENT OF CANCER.
CL2008001076A1 (en) COMPOUNDS DERIVED FROM SULFONAMIDE; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF CANCER.
CL2007003774A1 (en) COMPOUNDS DERIVED FROM QUINAZOLINA SUBSTITUTES, INHIBITORS OF QUINASA; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF DISEASES SUCH AS CANCER, ATEROSCLEROSIS AND ARTHRITIS.
CL2007000161A1 (en) COMPOUNDS DERIVED FROM SUBSTITUTED 2,4-DIOXOIMIDAZOLIDINE, INHIBITORS OF KINE PROTEINS; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF DISEASES SUCH AS CANCER.
CL2007000806A1 (en) COMPOUNDS DERIVED FROM REPLACED HETEROPENTACICLOS; PREPARATION PROCESS; INTERMEDIARY COMPOUNDS; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF CANCER.
CL2009001274A1 (en) Substituted triazine-derived compounds, mediated by inhibition of p13 and mtor kinase; pharmaceutical composition; preparation procedure; and its use in the treatment of different types of cancer.
DK3567035T3 (en) N-SUBSTITUTED 2,5-DIOXO-AZOLINE COMPOUNDS FOR USE IN THE TREATMENT OF CANCER
BRPI0814889A2 (en) alpha7-selective ligand treatment.
DK2061561T3 (en) CANCER TREATMENT COMPOSITIONS
DK2195015T3 (en) Composition for the treatment of prostate cancer
DK1765391T3 (en) BACTERIAL PREPARATIONS FOR THE TREATMENT OF CANCER
CL2008002097A1 (en) Compounds derived from substituted fused heterocycles, phosphatidyl-inositol-3 kinase inhibitors; pharmaceutical composition; and use in the treatment of cancer.
DK1960370T3 (en) Pyridazinone derivatives for tumor treatment
CL2012000772A1 (en) Compounds derived from substituted carboxyamide heterocycles, ar antagonist; pharmaceutical composition comprising them; and use in the treatment of prostate cancer.
DK1868579T3 (en) Pharmaceutical composition comprising an omega-carboxyaryl sun-substituted diphenylurea for the treatment of cancer
WO2008046911A3 (en) Novel human micrornas associated with cancer
SMP200900085B (en) 3-imidazolyl-indoles for the treatment of malolysiseproliferative.